Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which surgery best fixes macular holes? new trial aims to find out

NCT ID NCT07606404

Disease control Sponsor: Kazakh Eye Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing ten different surgical methods to repair full-thickness macular holes, a condition that blurs central vision. 120 adults will be randomly assigned to one technique during vitrectomy surgery. The main goal is to see which method closes the hole most often and gives the best eyesight, measured at one week, one month, and one year after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pars plana vitrectomy surgery with various techniques, plus optional use of platelet-rich plasma or amniotic membrane graft
What this could lead to
If successful, this study could identify the most effective surgical technique for closing macular holes and improving vision, guiding future standard care.
What could go wrong
This is a single-center trial with 120 participants, so results may not apply to all patients. Different techniques may work better for different hole sizes, and individual outcomes vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults aged ≥18 years. Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV). Symptom duration ≤12 months. Clear ocular media sufficient for high-quality OCT imaging. No prior pars plana vitrectomy in the study eye. No severe foveal atrophy on OCT. Able and willing to comply with postoperative positioning and follow-up visits. Written informed consent provided. Exclusion Criteria: A. Etiology-Related / Secondary Macular Holes: Traumatic macular hole. High myopia with posterior staphyloma (axial length \>28 mm and/or spherical equivalent ≤-8.0 D). Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy. Retinal vascular occlusion-related macular hole. Uveitis-related macular hole. Advanced age-related macular degeneration (AMD) with foveal atrophy. B. Prior Interventions: Any prior pars plana vitrectomy in the study eye. C. Ocular Conditions That May Affect Outcomes or Safety: Active or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis). Uncontrolled glaucoma (intraocular pressure \>28 mmHg despite treatment). Media opacity precluding adequate OCT (e.g., dense cataract or corneal opacity). Geographic atrophy involving the fovea.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macular holes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular holes retinal perforation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular holes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kazakh Eye Research Institute

    RECRUITING

    Almaty, Almaty, 050042, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.